HRD1 inhibits fatty acid oxidation and tumorigenesis by ubiquitinating CPT2 in triple‐negative breast cancer
Open Access
- 18 November 2020
- journal article
- research article
- Published by Wiley in Molecular Oncology
- Vol. 15 (2) , 642-656
Abstract
Dependence on glutamine and acceleration of fatty acid oxidation (FAO) are both metabolic characteristics of triple‐negative breast cancer (TNBC). With the rapid growth of tumors, accelerated glutamine catabolism depletes local glutamine, resulting in glutamine deficiency. Studies have shown that the use of alternative energy sources, such as fatty acids, enables tumor cells to continue to proliferate rapidly in a glutamine‐deficient microenvironment. However, the detailed mechanisms behind this metabolic change are still unclear. Herein, we identified HRD1 as a regulatory protein for FAO that specifically inhibits TNBC cell proliferation under glutamine‐deficient conditions. Furthermore, we observed that HRD1 expression is significantly downregulated under glutamine deprivation and HRD1 directly ubiquitinates and stabilizes CPT2 through K48‐linked ubiquitination. In addition, the inhibition of CPT2 expression dramatically suppresses TNBC cell proliferation mediated by HRD1 knockdown in vitro and in vivo. Finally, we found that the glutaminase inhibitor CB839 significantly inhibited TNBC cell tumor growth, but not in the HRD1 knock‐downed TNBC cells. These findings provide an invaluable insight into HRD1 as a regulator of lipid metabolism and have important implications for TNBC therapeutic targeting.Keywords
Funding Information
- National Natural Science Foundation of China (81572582, 81672440, 81972625)
- Doctoral Start-up Foundation of Liaoning Province (20180540092)
- Dalian Institute of Chemical Physics, Chinese Academy of Sciences (DICP ZZBS201803)
This publication has 34 references indexed in Scilit:
- Hrd1-mediated BLIMP-1 ubiquitination promotes dendritic cell MHCII expression for CD4 T cell priming during inflammationJournal of Experimental Medicine, 2014
- Hrd1 suppresses Nrf2-mediated cellular protection during liver cirrhosisGenes & Development, 2014
- Ubiquitin Ligases in Cholesterol MetabolismDiabetes & Metabolism Journal, 2014
- Defining human ERAD networks through an integrative mapping strategyNature Cell Biology, 2011
- Glutamine addiction: a new therapeutic target in cancerTrends in Biochemical Sciences, 2010
- Triple-negative breast cancer—current status and future directionsAnnals of Oncology, 2009
- Characterization of an ERAD Pathway for Nonglycosylated BiP Substrates, which Require HerpMolecular Cell, 2007
- Molecular Classification and Molecular Forecasting of Breast Cancer: Ready for Clinical Application?Journal of Clinical Oncology, 2005
- Role of 26S proteasome and HRD genes in the degradation of 3-hydroxy-3-methylglutaryl-CoA reductase, an integral endoplasmic reticulum membrane protein.Molecular Biology of the Cell, 1996
- Regulated degradation of HMG-CoA reductase, an integral membrane protein of the endoplasmic reticulum, in yeast.Journal of Cell Biology, 1994